Literature DB >> 18681776

Pharmacogenomic importance of ABCG2.

George Cusatis1, Alex Sparreboom.   

Abstract

The ATP-binding cassette transporter ABCG2 (BCRP, MXR and ABCP) is highly expressed in the gastrointestinal tract and liver, and governs absorption, distribution and excretion of a wide variety of clinically important drugs. Common germline polymorphisms in the ABCG2 gene have been described that can affect expression, cellular localization and/or substrate recognition of the encoded protein. Alteration of transporter function by either of these mechanisms contributes significantly to interindividual variability in drug disposition and treatment outcome with certain, but not all, substrates for ABCG2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18681776     DOI: 10.2217/14622416.9.8.1005

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  21 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 4.  ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.

Authors:  Maryam Hosseini Hasanabady; Fatemeh Kalalinia
Journal:  J Biosci       Date:  2016-06       Impact factor: 1.826

Review 5.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

6.  Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.

Authors:  Carole Saison; Virginie Helias; Bryan A Ballif; Thierry Peyrard; Hervé Puy; Toru Miyazaki; Sébastien Perrot; Muriel Vayssier-Taussat; Mauro Waldner; Pierre-Yves Le Pennec; Jean-Pierre Cartron; Lionel Arnaud
Journal:  Nat Genet       Date:  2012-01-15       Impact factor: 38.330

7.  Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.

Authors:  Paola Di Gion; Friederike Kanefendt; Andreas Lindauer; Matthias Scheffler; Oxana Doroshyenko; Uwe Fuhr; Jürgen Wolf; Ulrich Jaehde
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

8.  Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.

Authors:  Orsolya Polgar; Caterina Ierano; Akina Tamaki; Bradford Stanley; Yvona Ward; Di Xia; Nadya Tarasova; Robert W Robey; Susan E Bates
Journal:  Biochemistry       Date:  2010-03-16       Impact factor: 3.162

Review 9.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

Review 10.  Skin toxicities associated with epidermal growth factor receptor inhibitors.

Authors:  Tianhong Li; Roman Perez-Soler
Journal:  Target Oncol       Date:  2009-05-19       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.